| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1994;108:1132-1137
© 1994 Mosby, Inc.
GENERAL THORACIC SURGERY |
Cleveland, Ohio
Address for reprints: Thomas W. Rice, MD, Department of Thoracic and Cardiovascular Surgery, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.
Abstract
Barrett's esophagus is a metaplastic condition with an unpredictable potential for neoplasia. Mutations of the tumor-suppressor gene p53 have been implicated in the evolution of some carcinomas. These mutations frequently result in intranuclear protein accumulation, which can be detected immunohistochemically. This study was undertaken to determine whether p53 immunoreactivity in Barrett's esophagus is a marker of neoplasia and, if so, when it occurs in the metaplasia-dysplasia-carcinoma sequence. Twenty-eight esophageal resection specimens were studied. Barrett's mucosa was present in each specimen, low-grade dysplasia in 27, high-grade dysplasia in 26, intramucosal cancer in 18, and submucosal cancer in 5. Immunohistochemical staining with the monoclonal antibody Pab1801 was used to detect the intranuclear protein product of mutated p53. No p53 immunoreactivity was seen in specimens of Barrett's mucosa or low-grade dysplasia. p53 immunoreactivity was found only in specimens of high-grade dysplasia, intramucosal cancer, and submucosal cancer. Sixty-nine percent (18/26) of these specimens exhibited mutated p53; 18 of 26 specimens of high-grade dysplasia (69%), 12 of 18 intramucosal cancer specimens (67%), and two of five submucosal cancer specimens (40%) expressed mutated p53. When p53 staining was observed, the spectrum of neoplastic changes (high-grade dysplasia, intramucosal cancer, submucosal cancer) within the specimen was positive. We conclude that (1) p53 immunoreactivity in Barrett's esophagus is a frequent, but not inclusive, marker for high-grade dysplasia, intramucosal cancer, and submucosal cancer and (2) immunoreactivity occurs late in the metaplasia-dysplasia-carcinoma sequence, during the transition to high-grade dysplasia. (J THORAC CARDIOVASC SURG 1994;108:1132-7)
This article has been cited by other articles:
|
|
 |
|
  A. G. Casson, S. C. Evans, A. Gillis, G. A. Porter, P. Veugelers, S. J. Darnton, D. L. Guernsey, and P. Hainaut Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1121 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Kaur and G. Triadafilopoulos Acid- and bile-induced PGE2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent Am J Physiol Gastrointest Liver Physiol, August 1, 2002; 283(2): G327 - G334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Schneider, O. Stoeltzing, J. A. Roth, A. H. Hoelscher, S. Wegerer, S. Mizumoto, K. Becker, H.-J. Dittler, U. Fink, and J. R. Siewert p53 Mutational Status Improves Estimation of Prognosis in Patients with Curatively Resected Adenocarcinoma in Barrett's Esophagus Clin. Cancer Res., August 1, 2000; 6(8): 3153 - 3158. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Katada, R. A. Hinder, T. C. Smyrk, N. Hirabayashi, G. Perdikis, R. J. Lund, T. Woodward, and P. J. Klingler Apoptosis Is Inhibited Early in the Dysplasia-Carcinoma Sequence of Barrett Esophagus Arch Surg, July 1, 1997; 132(7): 728 - 733. [Abstract] [PDF]
|
|
|
|
 |
|
 A. G. Little Barrett's Esophagus Ann. Thorac. Surg., July 1, 1996; 62(1): 315 - 315. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
